PASSAGE BIO INC

PASGNASDAQ

🏆 #4867 by market capUS Equity

$4.67▲ $0.09 (+1.97%)

After hours · at close

🔔

Track PASG

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 2.0%

7d▼ 3.6%

14d▼ 1.9%

30d▲ 3.3%

ytd▼ 59.9%

1y▼ 42.2%

🏦Market Cap

$15M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $4.61 – $4.70
52-Week Range: $3.29 – $20.00
Volume: $1.90B
Avg Volume: $2.53B
Shares Outstanding: 3.2M
Next Earnings: Dec 9, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $543,096
P/E Ratio: -0.4
P/S Ratio: 0.0x
EPS (TTM): $-11.25
Dividend Yield: 0.00%
Dilution (1yr): +2.2%

Why Investors Own PASG

✓High-growth profile — revenue up +41.7% YoY with expanding US Equity exposure.
✓Healthy economics — 57% gross margin and 30% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PASSAGE BIO INC

PASG

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$43M▼ −38.7% YoY

Free Cash Flow

−$32M▼ −34.3% YoY

Shares Outstanding

3.2M▲ +2.2% YoY

Net Cash

$22M▲ +$10M YoY

StockOtter · stockotter.space

About PASSAGE BIO INC

Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.

🦦